Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech has entered into an agreement with Leede Jones Gable to purchase 6,667,000 units on a bought-deal basis for gross proceeds of $15M at $2.25/unit.
July 31, 2023 | 10:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech's agreement with Leede Jones Gable for a bought-deal purchase of 6,667,000 units could potentially increase the company's liquidity.
The deal between Oncolytics Biotech and Leede Jones Gable is a significant financial move. The bought-deal purchase of 6,667,000 units will provide Oncolytics Biotech with $15M in gross proceeds, potentially increasing the company's liquidity and financial stability. This could positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100